Dr. Adrian Shifren, MD

Dr. Shifren practices at Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health.

Dr. Shifren's NPI, 1013933233, was assigned on July 14, 2006. Dr. Shifren holds Missouri license 2001006984.

Dr. Shifren's primary practice is Barnes-Jewish Hospital, at One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110 in St. Louis City. The practice phone is (314) 747-3000. Dr. Shifren also practices at Barnes-Jewish Hospital, 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110.

Dr. Shifren's primary practice is Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health. Dr. Shifren is also affiliated with Missouri Baptist Medical Center. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Shifren to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shifren practices, 6 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Shifren's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Shifren is licensed in Missouri.

CMS data shows 815 Medicare services from Dr. Shifren across 15 procedure codes in 2024, for 415 Medicare patients. Medicare paid $45,909 for them.

CMS counts 415 Medicare patients who saw Dr. Shifren in 2024. The largest group is 65 to 74, with 197 patients. 75% of them have high blood pressure, and 71% have high cholesterol. 18% are also on Medicaid. Their average risk score is 2.34, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shifren's median patient age at 70, with 58% women.

In 2024, Dr. Shifren wrote 1,587 Medicare Part D claims for 228 patients. 53% of them were for generic drugs. CMS names the drug for 1,438 of them, across 31 drugs with 11 or more claims each, at $2,977,224 in total drug cost. In 2023, CMS named 1,282 claims across 29 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Shifren for performance year 2024, reported as part of a group. Dr. Shifren accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 14 papers to Dr. Shifren, published from 2011 to 2021. 2012 was the busiest year, with 2. The most frequent topics are Idiopathic Pulmonary Fibrosis, Lung and Randomized Controlled Trials as Topic. Dr. Shifren's most frequent co-authors are Derek Ernest Byers, MD, Delphine L. Chen, MD and Howard Jeng Huang, MD.

Dmand AI links Dr. Shifren to 3 clinical trials. Conditions studied include Pulmonary Fibrosis, Asthma and Idiopathic Pulmonary Fibrosis.

CMS Open Payments shows 125 general payments to Dr. Shifren from 4 drug and device companies from 2016 to 2023. Speaker and faculty fees make up the largest share, 76% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $61,646.